Prescription trends at the end of life in a palliative care unit: observational study

Tatiana Peralta1*, Maria Margarida Castel-Branco2,3, Paulo Reis-Pina4,5, Isabel Vitória Figueiredo2,3 and Marília Dourado1,6,7

Abstract

Background: Symptomatic control is essential in palliative care, particularly in end-of-life, in which the pathophysiological changes that characterize this last phase of life strengthen the need to carry out an early therapeutic review. Hence, we aim to evaluate the prescribing pattern at a palliative care unit at two different time points: on admission and the day of the patient’s death.

Methods: Quantitative, analytic, longitudinal, retrospective and observational study. Participants were adult patients who were admitted and died in a palliative care unit, in Portugal. Sociodemographic, clinical and pharmacological data were collected, including frequencies and routes of administration of schedule prescribed drugs and rescue drugs, from the day of admission until the day of death.

Results: 115 patients were included with an average age of 70.0 ± 12.9 years old, 53.9 were male, mostly referred by the Hospital Palliative Care Support Teams. The most common pathology was cancer, mainly in advanced stage. On admission, the median scheduled prescription was seven and “as needed” was three drugs. On the day of death, a decrease of prescriptions was observed. Opioids were always the most prescribed drugs. Near death, there was a higher tendency to prescribe butylscopolamine, midazolam, diazepam and levomepromazine. The most frequent route of drug administration was oral on admission and subcutaneous on the day of death.

Conclusions: Polypharmacy is a reality in palliative care despite specialist palliative care teams. A reduction of prescribed drugs was verified, essentially due less comorbidity-oriented drugs. Further studies are required to analyse the importance of Hospital Palliative Care Support Teams.

Keywords: Drug prescription, Prescription trends, Deprescribing, Palliative care, End of life care, Hospice care

Background

Palliative Care (PC) is an integral, multidisciplinary, yet specialized medical care. PC focus is on relieving patients’ symptoms and improving the quality of life of both patients and their families when facing progressive, incurable, or life threatening diseases [1, 2]. Knowing that PC has a positive impact on the relief of suffering, comfort, and quality of life of all involved, PC should be offered as early as possible to all who can benefit from it [1]. In Portugal, as in other countries, PC needs are expected to continue to increase as the population ages [1]. The National Palliative Care Network, approved since 2012, was developed in a collaborative and integrated model involving the three healthcare levels of the National Health Service (Primary Healthcare, Hospital Healthcare and Integrated Continuous Care) [1].

PC is of great importance in the terminal phase of illness, i.e., during the last 3–6 months of life when symptom control and quality of life are essential [3–5]. Thus, it is necessary to identify symptoms early and treat them.
rigorously with multiple drugs. However, prescription in PC has some peculiarities arising from the physiological changes that the end-of-life (EOL) human body goes through. There are pharmacokinetic and pharmacodynamics modifications that change the risk/benefit ratio of prescription [3–6].

Moreover, the advanced stage of most pathologies, in an increasingly aged population with several comorbidities is a factor that contributes to the complexity of patients. In this context, polypharmacy (understood as the simultaneous taking of five or more drugs) is common and is often associated with the occurrence of pharmacological interactions and adverse drug events [7, 8].

When death is imminent it is necessary to simplify and withdraw unnecessary drugs, to optimize outcomes and reduce risks [7, 9–13]. In addition, it is desirable to increase the prescription of drugs used in controlling symptoms, relief of suffering, and providing comfort [7, 14, 15]. The major outcome becomes quality of life and avoid polypharmacy [3, 5–7, 15]. Extending life or preventing disabilities becomes secondary [3].

The objective of this study was to analyse the prescription pattern in a palliative care unit (PCU), at two different time points: 1) on admission (prior to the PCU team intervention) and 2) on the day of death. A secondary objective was to identify the most prescribed subgroup of drugs, the prescription prevalence, and the most used routes of administration.

Material and methods
Type of study and sample
This was a quantitative, analytic, longitudinal, retrospective and observational study. It included all adult patients admitted to the Poverello’s PCU in Braga, Portugal between August 1st, 2017 and December 31st, 2018. We excluded patients discharged to other institutions or home as well as patients with absent or incomplete clinical information.

Definition of the variables and methods
Data extracted from clinical records included gender, age, provenance, diagnosis, number of comorbidities, functional status (using the Palliative Performance Scale - PPS) and the length of stay (in days) at the institution. We collected data regarding prescription at admission (T0) and on the day of death (T1), i.e., the number of prescribed drugs at fixed intervals of time or “scheduled prescription” (SP) and pro re nata “as needed” (PRN). The name of the drug (according to the international common name), the pharmacological subgroup (up to the second subgroup of the Anatomical Therapeutic Chemical Code - ATC), and the route of drug administration were also collected.

Statistical analysis
Categorical variables were expressed with absolute and relative frequencies: n (%). Continuous variables were presented as mean and standard deviation (SD) or median and interquartile interval, Mdn (Q1,Q3). The normality of continuous variables was assessed by the Kolmogorov-Smirnov test. The McNemar test was used for comparisons between pharmacologic subgroups (SP and PRN) and prescribed drugs at T0 and T1. Chi-square tests for categorical variables were used to check for associations. The routes of administration were compared using a z score test for two population proportions. The Wilcoxon test was used to compare paired continuous variables. The software IBM-Statistical Package for the Social Sciences (v24) was used, and statistical significance was set at p < 0.05 (two sided).

Results
During the study period, 145 patients were admitted to the PCU. We excluded 26 patients who were discharged and four who had unavailable prescription information. Hence, 115 patients were included. The average age was 70.0 ±12.9 years old; 53.9% were male. Referrals to the PCU were done mostly by the Hospital Palliative Care Support Teams (90.4%). Cancer was the most frequent diagnosis (84.3%) mainly in advanced stage (56.7%) and predominantly lung cancer (20.6%). Most patients (73.9%) had two or more comorbidities and persistent complex needs. Most patients (88.8%) had major functional limitations with reduced mobility, need for assistance in basic daily activities, oral route limitations, and periods of altered state of consciousness (PPS <50) (Table 1). Half of the patients were admitted in the last 2 weeks of life. The median length of stay in the PCU was 10 (5; 33) days, and 13.0% died in the first 48 hours after admission.

Characterization of drug prescription
Quantitative analysis
Considering the total of prescriptions (T0+T1), 167 different drugs were prescribed making up to 2270 prescriptions. There were 65 different pharmacological subgroups; T1 drugs from 20 identified subgroups were deprescribed, e.g., ATC A07A, B03B, G03A, M03B, and C09C. In SP, patients were prescribed a median of 7 (5; 10) drugs at T0 decreasing to 4 (3; 7) drugs at T1 ($p <0.001$). In PRN, the median prescription increased from 3 (2; 4) to 4 (3; 5) drugs ($p <0.001$) (Table 2).
Table 1  Characteristics of the patients included in the study  
(n = 115)

| Characteristics                          | N = 115 |
|------------------------------------------|---------|
| Age (years), mean± SD                    | 70.0±12.9 |
| Length of hospitalization (days), Mdn (Q1,Q3) | 10 (5,33) |
| Gender, n (%)                           |         |
| Male                                     | 62 (53.9) |
| Female                                   | 53 (46.1) |
| Provenance, n (%)                       |         |
| HPCST                                    | 104 (90.4) |
| CCICT                                    | 11 (9.6) |
| Primary diagnosis, n (%)                 |         |
| Cancer                                   | 97 (84.3) |
| Heart failure                            | 5 (4.3) |
| COPD                                     | 3 (2.6) |
| Ulcers                                   | 3 (2.6) |
| Renal failure                            | 2 (1.7) |
| Other                                    | 5 (4.5) |
| Location primary cancer, n (%)           |         |
| Lung                                     | 20 (20.6) |
| Stomach                                  | 11 (11.3) |
| Colorectal                               | 11 (11.3) |
| Central nervous system                   | 9 (9.3) |
| Head and Neck                            | 6 (6.1) |
| Esophagus                                | 6 (6.1) |
| Pancreas                                 | 6 (6.1) |
| Liver                                    | 4 (4.1) |
| Uterus                                   | 4 (4.1) |
| Other                                    | 20 (20.6) |
| Extension of disease, n (%)              |         |
| Metastatic                               | 55 (56.7) |
| Locally advanced /unknown                | 42 (43.3) |
| Co-morbid conditions, n (%)              |         |
| 1                                        | 20 (17.4) |
| 2 to 4                                   | 64 (55.7) |
| > 4                                      | 21 (18.2) |
| None/ unknown                            | 10 (8.7) |
| PPS, n (%)                               |         |
| ≤ 20                                     | 29 (27.1) |
| 30                                       | 29 (25.2) |
| 40                                       | 37 (32.2) |
| 50                                       | 11 (9.6) |
| 60                                       | 1 (0.9) |

*SD* Standard deviation, *Mdn* Median, *Q1* first quartile, *Q3* third quartile, n (%) number (percentage), *HPCST* Hospital Palliative Care Support Teams, *CCICT* Continuity of care/Integrated Care Teams, *COPD* Chronic obstructive pulmonary disease, *PPS* the Palliative Performance Scale

### Qualitative analysis

Opioids analgesics were the most prescribed subgroup in SP both at T0 (73.0%) and at T1 (82.6%) with a statistically significant increase (*p* = 0.013) (Table 3).

Antispasmodics (A03B) were the second most prescribed subgroup in T1. From T0 (13.0%) to T1 (52.2%), we found a significant increase in its prescription (*p* < 0.001). Corticosteroids, were the third most prescribed class at T1. They increased from 40.0% (T0) to 45.2% (T1) without statistical significance (*p* = 0.392). We found that 84.8% of patients undergoing corticosteroid therapy at T0 were treated concomitantly with antiulcer agents (*p* = 0.001). At T1, no statistical association was found between anti-ulcers agents and corticosteroid prescription (*p* = 0.054).

Laxatives (A06A) were the third most prescribed subgroup in T0 that decreased from 55.7% (T0) to 25.2% (T1) with statistically significant (*p* < 0.001). No association was found between opioid and laxatives prescription in SP [*p* = 0.190 (T0) and *p* = 0.678 (T1)] nor between opioid in SP and laxatives in PRN prescription [*p* = 0.194 (T0) and *p* = 0.134 (T1)].

Regarding anti-dyslipidemiantis, including statins, we found 5.2% of prescription in T0, having been deprescribed in 83.3% of patients in T1.

Hypoglycaemic agents (A10A and A10B) were withdrawn in both regimes, and statistical significance was found only in PRN [14.8% (T0), 6.1% (T1); *p* = 0.031].

As to drugs with antihypertensive potential (subgroups ATC C02A, C03B, C03C, C03D, C07A, C08C, C08D, C09A and C09C), there was a statistically significant reduction in the prescription [38.3% (T0) to 27.0% (T1), *p* < 0.029]. The proportion of antithrombotic agents prescribed reduced from 35.7 (T0) to 9.6% (T1) (*p* < 0.001). The use of antidepressants decreased significantly from 41.7% (T0) to 18.3% (T1) (*p* < 0.001).

Considering PRN prescription, opioids were the most prescribed subgroup with statistical difference between T0 (76.5%) and T1 (92.2%; *p* = 0.001) (Table 4). Analgesics and antipyretics represent the second most prescribed subgroup in T0 (45.2%). At T1, antipsychotics were the second most prescribed class with a significant increase in prescription compared to T0 (20.0% (T0), 64.3% (T1), *p* < 0.001). Propulsive, i.e., metoclopramide, were prescribed upon 25.2% (T0), 38.3% (T1), *p* < 0.001). No association was found between antiulcers agents and corticosteroid prescription (*p* = 0.054).

For PRN, we found a statistically significant increase in the prescription of morphine (*p* < 0.001), metoclopramide
(p = 0.032), diazepam (p < 0.001), butylscopolamine (p < 0.001), and bisacodile (p < 0.001). There was a statistically significant decrease between T0 and T1 in the prescription of docusate Na+ and sorbitol (p < 0.001), insulin (human) (p = 0.031) and Na+ laurylsulfoacetate and citrate (p < 0.001).

Administration routes
At T0, medication was administered mostly orally either in SP (70.3%) or in PRN (28.7%). At T1, there was a significant decrease in the use of oral route, which in SP decreased to 41.6% (p < 0.001) and in PRN to 7.2% (p < 0.001).

In T0, the intravenous route was used in both SP (4.8%) and PRN (16.7%). We found a decrease in the use of this route in T1 both in SP (0.3%) and in PRN (0.7%).

The subcutaneous route increased at T1 both in SP [from 12.4% (T0) to 47.3% (T1), p < 0.001] and in PRN [from 36.9% (T0) to 64.7% (T1), p < 0.001].

The continuous perfusion by the subcutaneous route was used at T0 in 7.0% and at T1 in 40.9% of patients. At SP, there was subcutaneous administration of metoclopramide, dexamethasone, morphine, butylscopolamine, and furosemide. Concerning PRN, the subcutaneous route was used to administer haloperidol, lorazepam, and dexamethasone.

### Table 2
Description of schedule prescribed drugs and “as needed” drugs (n = 115)

| ATC code | Drug subgroup                                | Scheduled prescription n (%) | p-value |
|----------|----------------------------------------------|------------------------------|---------|
| A02B     | Drugs for peptic ulcer and gastro-oesophageal reflux disease | 77 (67.0) 25 (21.7) | <0.001 |
| A06A     | Drugs for constipation                        | 64 (55.7) 29 (25.2) | <0.001 |
| N06A     | Antidepressants                               | 48 (41.7) 21 (18.3) | <0.001 |
| H02A     | Corticosteroids for systemic use, plain       | 46 (40.0) 52 (45.2) | 0.392   |
| N03A     | Antiepileptics                                | 43 (37.4) 18 (15.7) | 0.265   |
| N05A     | Antipsychotics                                | 41 (35.7) 34 (29.6) | <0.001 |
| B01A     | Antithrombotic agents                         | 41 (35.7) 11 (9.6)  | <0.001 |
| N05B     | Anxiolytics                                   | 34 (29.6) 14 (12.2) | <0.001 |
| A03F     | Propulsives                                   | 38 (33.0) 22 (19.1) | <0.001 |
| C03C     | High-ceiling diuretics                        | 29 (25.2) 23 (20.0) | 0.307   |
| N05C     | Hypnotics                                     | 21 (18.3) 35 (30.4) | 0.16    |
| C07A     | Beta blocking agents                          | 17 (14.8) 7 (6.1)  | 0.006   |
| A03B     | Belladonna and derivatives, plain             | 15 (13.0) 60 (52.2) | <0.001 |
| C09A     | Angiotensin-converting enzyme inhibitors, plain | 7 (6.1) 1 (0.9)   | 0.031   |
| A10A     | Insulins and analogues                        | 6 (5.2) 5 (4.3) | 1.000   |
| C03D     | Potassium-sparing agents                      | 6 (5.2) 4 (3.5) | 0.727   |
| C10A     | Lipid modifying agents, plain                 | 6 (5.2) 1 (0.9) | 0.063   |
| A10B     | Blood glucose lowering drugs, excl. Insulins  | 5 (4.3) 2 (1.7) | 0.250   |
| C09C     | Angiotensin II receptor blockers, plain       | 4 (3.5) 0 | –       |
| C08C     | Selective calcium channel blockers with mainly vascular effects | 3 (2.6) 1 (0.9) | 0.625   |
| C08D     | Selective calcium channel blockers with direct cardiac effects | 2 (1.7) 0 | –       |
| C02A     | Antiadrenergic agents, centrally acting       | 1 (0.9) 0 | –       |
| C03B     | Low-ceiling diuretics, excl. Thiazides        | 1 (0.9) 1 (0.9) | 1.000   |

T0- at admission. T1- the day of death. ATC- the Anatomical Therapeutic Chemical Code

* McNemar Test

b statistically significant at 5%

### Table 3
Most common schedule prescribed drug subgroup at admission and the day of death

| ATC code | Drug subgroup                                | Scheduled prescription | p-value |
|----------|----------------------------------------------|------------------------|---------|
| N02A     | Opioid analgesics                            | 84 (73.0) 95 (82.6) | 0.013   |
| A02B     | Drugs for peptic ulcer and gastro-oesophageal reflux disease | 77 (67.0) 25 (21.7) | <0.001 |
| A06A     | Drugs for constipation                        | 64 (55.7) 29 (25.2) | <0.001 |
| N06A     | Antidepressants                               | 48 (41.7) 21 (18.3) | <0.001 |
| H02A     | Corticosteroids for systemic use, plain       | 46 (40.0) 52 (45.2) | 0.392   |
| N03A     | Antiepileptics                                | 43 (37.4) 18 (15.7) | 0.265   |
| N05A     | Antipsychotics                                | 41 (35.7) 34 (29.6) | <0.001 |
| B01A     | Antithrombotic agents                         | 41 (35.7) 11 (9.6)  | <0.001 |
| N05B     | Anxiolytics                                   | 34 (29.6) 14 (12.2) | <0.001 |
| A03F     | Propulsives                                   | 38 (33.0) 22 (19.1) | <0.001 |
| C03C     | High-ceiling diuretics                        | 29 (25.2) 23 (20.0) | 0.307   |
| N05C     | Hypnotics                                     | 21 (18.3) 35 (30.4) | 0.16    |
| C07A     | Beta blocking agents                          | 17 (14.8) 7 (6.1)  | 0.006   |
| A03B     | Belladonna and derivatives, plain             | 15 (13.0) 60 (52.2) | <0.001 |
| C09A     | Angiotensin-converting enzyme inhibitors, plain | 7 (6.1) 1 (0.9)   | 0.031   |
| A10A     | Insulins and analogues                        | 6 (5.2) 5 (4.3) | 1.000   |
| C03D     | Potassium-sparing agents                      | 6 (5.2) 4 (3.5) | 0.727   |
| C10A     | Lipid modifying agents, plain                 | 6 (5.2) 1 (0.9) | 0.063   |
| A10B     | Blood glucose lowering drugs, excl. Insulins  | 5 (4.3) 2 (1.7) | 0.250   |
| C09C     | Angiotensin II receptor blockers, plain       | 4 (3.5) 0 | –       |
| C08C     | Selective calcium channel blockers with mainly vascular effects | 3 (2.6) 1 (0.9) | 0.625   |
| C08D     | Selective calcium channel blockers with direct cardiac effects | 2 (1.7) 0 | –       |
| C02A     | Antiadrenergic agents, centrally acting       | 1 (0.9) 0 | –       |
| C03B     | Low-ceiling diuretics, excl. Thiazides        | 1 (0.9) 1 (0.9) | 1.000   |
Table 4  Most common “As Needed” drug subgroup at admission (T0) and the day of death (T1)

| ATC-code | Drug subgroup                                      | Prescription “as needed” | p-value^a |
|----------|---------------------------------------------------|--------------------------|-----------|
|          |                                                   | T0  | T1  |          |            |
|          |                                                   | n (%) | n (%) |          |            |
| N02A     | Opioid analgesics                                 | 88  | 106 | 0.001b  |            |
| N02B     | Non-opioid analgesics and antipyretics            | 52  | 57  | 0.552    |            |
| A06A     | Drugs for constipation                            | 41  | 34  | 0.324    |            |
| A03F     | Propulsives                                       | 29  | 44  | 0.032b   |            |
| N05C     | Hypnotics                                         | 24  | 32  | 0.215    |            |
| N05A     | Antipsychotics                                    | 23  | 74  | <0.001b  |            |
| A10A     | Insulins and analogues                            | 17  | 7   | 0.031b   |            |
| A04A     | Antiemetics and antinauseants                     | 9   | 5   | 0.289    |            |
| A03B     | Belladonna and derivatives, plain                 | 4   | 25  | <0.001b  |            |
| A02B     | Drugs for peptic ulcer and gastro-oesophageal reflux disease | 2   | 0   | –        |            |
| C09A     | Angiotensin-converting enzyme inhibitors, plain   | 2   | 1   | 1.000    |            |
| M01A     | Antinflammatory and antirheumatic products, non-steroids | 1   | 2   | 1.000    |            |
| B02A     | Antifibrinolytics                                 | 1   | 5   | 0.219    |            |
| A07D     | Antipropulsives                                   | 0   | 2   | –        |            |

T0- at admission. T1- the day of death. ATC- the Anatomical Therapeutic Chemical Code

^a McNemar Test

^b statistically significant at 5%
butylscopolamine, ondansetron, metoclopramide, and morphine. Figs. 1 and 2 show remaining routes of administration and individual drugs.

Discussion

Quantitative analysis

This study demonstrated that polypharmacy was present at EOL although there was a tendency to reduce the prescription of regular fixed drugs and increase of rescue drugs.

With no consensus on the issue, polypharmacy is usually defined as the simultaneous use of multiple drugs (frequently more than five) [8]. Side effects can occur in up to 80% of people when seven or more drugs are prescribed [14, 15]. We found that polypharmacy was present in more than half of the patients studied. On admission, patients had a median of seven schedule prescribed drugs and three “as needed” drugs. The median of schedule prescribed drugs at admission and at day of death was consistent with the existing literature [14, 16–19].

A reduction of drugs prescriptions from admission to death was verified, essentially due to the decrease in drugs aimed to treat or control comorbidities—some of these are considered potentially inappropriate [17, 18, 20–22]. Potentially inappropriate drugs were defined as drugs with increased risk for adverse events that outweigh eventual benefits, prevention of illnesses without short-term benefit, or conflicts with individual patient’s care goals [9, 20, 21]. Most patients were referred from Hospital Palliative Care Support Teams, a specialist palliative care team, that provide support and expert advice to complex situations [1]. Despite specialist palliative care consultation, polypharmacy continues to be an issue that might be explained to limitations related to human resources, training level, level of integration and development of palliative care programmes and survival prognostication [1, 23–25].

Deprescribing is a complex process that requires a careful assessment of the benefits and harms for patients and requires shared decision-making between doctors, patients, and pharmacists, which is not always easy [4, 12, 18, 21, 22, 26]. Frequent and systematic re-evaluation of the adequacy and safety of the prescription over time— as well as the appropriateness and effective cessation—are required [3, 13, 20, 21].

The significant increase observed in “as needed” prescription from admission to death was explained by the increased prescription of analgesics and antipsychotics [22]. This is consistent with other studies such as Sera et al. who reported 7.9 per patient “as needed” drugs used for pain relief, delirium, and anxiety for patients in a PCU [15, 27, 28].

Qualitative analysis

Pharmacological subgroups considered potentially inappropriate include dyslipidaemic drugs (particularly statins). Here, we found a lower prescription proportion than other studies at admission (5% vs 29%); most of them were withdrawn [16, 18, 27, 29]. Statins are not considered useful in patients with limited life expectancy and at EOL [18]. These drugs can be associated with several problems such as myopathy, myalgia, liver dysfunction, and acute renal failure among others. Some multicentre studies have shown that there are no benefits to cardiovascular prevention when life expectancy is limited [30, 31]. Therefore statins withdrawal is safe and is associated with a significant improvement in quality of life [30–33].

We found a significant deprescription of antihypertensive drugs that could suggest that these drugs might be futile at this stage [6, 18]. However, this subgroup
includes diuretics drugs such as furosemide that are widely used in PC for symptomatic control [2].

Antithrombotic agents were also significantly depre-
scribed with a preference to low-molecular weight heparin, mainly enoxaparin, both at admission and at the day of death. Research regarding the risk of thrombosis in EOL is scarce however the administration of heparin seems to have no impact on patient survival [32, 34–36].

We found that antiulcer drugs were prescribed both at admission (68.9%) and at death (21.8%) more than what was found in other studies [14, 18, 27, 34]. In our study, patients with corticosteroid are more likely to have antiu-

lcer agents at admission. Prescription appropriateness such as history of gastrointestinal bleeding, peptic ulcer, gastritis, or chronic use of non-steroidal anti-inflammato-

ry drugs for more than 30 days has not been assessed. In PC setting, antiulcer drugs can be considered futile upon 50% of prescriptions [16, 18, 27, 32].

Diabetic treatment in patients in PC can conflict with quality of life due to injections and glycaemic control that can explain the withdrawal of “as needed” hypoglycaemic drugs. We have not assessed hyperglycaemia symptoms [37–39].

Metoclopramide is a propulsive drug and is recom-

mended for the first line management of nausea and vomiting explaining the increased “as needed” prescription observed at day of death [2, 40].

Butylscopolamine, was one of the most prescribed drugs at day of death in both prescription regimes. This anticholinergic drug relaxes smooth muscles and reduces secretions from the respiratory and digestive tract, which helps to control some of the most prevalent symptoms in PC such as nausea and vomiting, pain, respiratory tract secretions, and intestinal obstruction [2, 41].

Common symptoms at EOL include anxiety, depression and sleep disturbance [2]. The prescription of antidepres-
sant decreased significantly. In this study, the subgroup of anxiolytics, diazepam was the most “as needed” pre-
scribed mainly by rectal administration. This is explained by the incompatibility with subcutaneous route of admin-
istration. In the hypnotic/sedative subgroup, midazolam was the most prescribed in both moments and prescription regimes. Unlike other anxiolytics, midazolam can be administered subcutaneously or intravenously with a rapid onset of action. It is used as a sedative and in sei-

zures. Neuroleptics/antipsychotics are useful to control several symptoms such as anxiety, psychomotor agita-
tion, and delirium/confusion [2]. Haloperidol is a first choice for agitation associated with delirium in EOL. It was highly prescribed “as needed” at admission and day of death [40, 41]. It can also be used for anxiety refractory to benzodiazepines, presence of psychotic symptoms, or secondary anxiety caused by corticosteroids. Haloperidol, levomepromazine and midazolam are essential drugs used in sedation including palliative sedation when refractory symptoms are present near death such as mas-
sive terminal haemorrhage, asphyxiation due to respira-
tory obstruction, or uncontrollable pain [2, 41].

Pain is one of the most impacting symptoms for patients, their families, and caregivers. It has multidimen-
sional and multisystem manifestations inducing a loss of quality of life [2]. In this study, opioid and non-
opoid analgesics were the most prescribed drugs on both regimes and moments. At day of death, a statistically sig-
nificant increase in opioid prescription was found, which is related to the need to ensure adequate pain control. Pain management requires a multimodal approach and might need adjuvant drugs such as corticosteroids, anti-

convulsants, and benzodiazepines [2]. In this study, the use of those drugs increased at the day of death.

Constipation has a multifactorial aetiology and can affect quality of life [2]. It is recommended that laxatives must be prescribed to patients receiving opioids, how-
ever we found no association between opioid and laxative prescription [2, 40].

Administration routes
Most patients receiving intravenous drugs at admission came from the hospital.

In EOL, the presence of vomiting, nausea, gastric stasis, dysphagia, as well as changes in the state of conci-

sciousness, intestinal obstruction, or others limits the use of oral administration and justifies the high frequency of subcutaneous prescription [2, 18]. The subcutaneous route is a suitable and effective route with fewer risks of local and systemic complications. Not all drugs can be administered subcutaneously according to the summary of their drug characteristics such as furosemide, levomepromazine, metoclopramide, dexamethasone, midazolam, and haloperidol. Off-label prescription is one of the main challenges of prescribing in PC that must be standardized in order to make the work of the PC teams safer [1].

Several limitations are known. First, this study is a retrospective and single-unit study. Second, the clinical appropriateness of prescribing practices such as indica-
tion or effectiveness has not been assessed. The time between referral to admission and the disease progres-
sion time were also not considered. Finally, the type of symptoms, suffering, and quality of life were not evalua-
ted.

Conclusion
Potentially inappropriate drugs are common in patients referred to PC units. Deprescription can be improved in Hospital PC Support Teams. From admission until death, there was a reduction in the
scheduled prescription drugs for related comorbidities and an increase in the number of rescue drugs used for symptomatic control. The subcutaneous route was the preferred route of administration at the time of death. Opioids were the most frequent subgroup prescribed. Off-label prescription is one of the challenges in PC prescribing. Despite these limitations, our study describes current prescription patterns in PC and demonstrates the complexity of EOL prescription. Efforts should be made into raising awareness of deprescription especially in the hospital setting and the focus on symptomatic control at the EOL.

Abbreviations
ATC: Anatomical Therapeutic Chemical code; EOL: End of life; PC: Palliative care; PCCU: Palliative care unit; PPS: Palliative Performance Scale; PRN: Pro re nata (as needed) prescription; SP: Scheduled prescription.

Acknowledgements
The authors would like to thank the Poverello’s Palliative Care Unit (Braga, Portugal) for the data collection for this study, and its staff for their assistance and kindness.

Authors’ contributions
TP was responsible for study concept, data collection, analysis, manuscript drafting and revision. MCB provided critical feedback and helped shape the research, analysis and manuscript. PRP was responsible for study design, contributed to data collection and manuscript drafting. IF provided critical feedback, help data analysis and interpretation and manuscript revision. MD contributed to conception and study design, coordination, participated in data analysis and interpretation as well as manuscript drafting and revision. All authors read and approved the final manuscript.

Funding
This study had no sponsorship.

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study protocol was performed in accordance with the relevant guidelines and regulations. Furthermore, it was submitted to the Ethics Committee of the Faculty of Medicine of the University of Coimbra, which issued a favourable opinion without ethical restrictions (Ref. CE‑113/2018). The study was approved by the Technical Direction of the PCU. Ethics Committee of the Faculty of Medicine of the University of Coimbra waived the need of informed consent. We declare that informed consent was not required and obtained as it is a retrospective study. All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflicts of interest regarding the content of this article.

Author details
1 Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 2 Pharmacology and Pharmaceutical Care Laboratory, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal. 3 Institute for Clinical and Biomedical Research (iCIBRI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

4 Palliative Care Unit ‘Bento Menni’, Casa de Saúde da Idanha, Sintra, Portugal. 5 Faculty of Medicine, University of Lisbon, Lisbon, Portugal. 6 Center for Studies and Development of Continuous and Palliative Care (CEDCPC), Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 7 Centre for Health Studies and Research of the University of Coimbra (CEISUC), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

Received: 2 July 2021 Accepted: 22 April 2022 Published online: 04 May 2022

References
1. Comissão Nacional de Cuidados Paliativos. Plano Estratégico para o Desenvolvimento dos Cuidados Paliativos: 2021/2022. Available from: https://www.acss.min-saude.pt/wp-content/uploads/2017/01/PEDCPC-2021_2022.pdf. [cited 2022 Feb 16].
2. Barbosa A. Manual de Cuidados Paliativos. 3rd ed. Lisboa: Faculdade de Medicina da Universidade de Lisboa; 2016.
3. Holmes H. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther. 2009;85:103–7.
4. Stevenson J, Abernethy AP, Miller C, Currow DC. Managing comorbidities in patients at the end of life. BMJ; 2004;329:909–12.
5. Cruz‑Jentoft AJ, Boland B, Resarch L. Drug therapy optimization at the end of life. Drugs Aging. 2012;29:11–21.
6. Lee HR, Yi SY, Kim DY. Evaluation of prescribing medications for terminal Cancer patients near death: essential or futile. Cancer Res Treat. 2013;45:220–5.
7. Kiernan KA, Wexler D, Masel EK, Gartner V, Watzke HH. Polypharmacy in the terminal stage of cancer. Support Care Cancer. 2016;24:2067–74.
8. Masnoon N, Shabb S, Kalisch‑Ellett L, Caughhey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230.
9. Akinbolade O, Husband A, Forrest S, Todd A. Deprescribing in advanced illness. Prog Palliat Care. 2016;24:268–71.
10. McNeil MJ, Kamal AH, Kutner JS, Ritchie CS, Aberrnethy AP. The burden of Polypharmacy in patients near the end of life. J Pain Symptom Manag. 2016;51:178–183.e2.
11. Morin L, Wasteson JW, Laroche M‑L, Fastbom J, Johnell K. How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study. Palliat Med. 2019;33:1080–90.
12. Romero I, Braga B, Rodrigues R, Neto IG. “Deprescribing”in end of life patients: a guide to improve clinical practice. Med Interna. 2018;25:45–87.
13. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couture D, Rigby D, et al. Reducing inappropriate Polypharmacy: the process of Deprescribing. JAMA Intern Med. 2015;175:827.
14. Masmann AD, van Dijk M, Tibboel D, Baar FPM, Mathôt RAA. Medication use during end‑of‑life care in a palliative care centre. Int J Clin Pharm. 2015;37:767–75.
15. Currow DC, Stevenson JP, Aberrnethy AP, Plummer J, Shelby‑James TM. Prescribing in palliative care as death approaches: polypharmacy in palliative care. J Am Geriatr Soc. 2007;55:590–5.
16. van Noorden RCTM, Lavrijsen JC, Hestherbeek MJAB, Bor H, Vissers KCP, Koopmans RCTM. Changes in prescribed drugs between admission and the end of life in patients admitted to palliative care facilities. J Am Med Dir Assoc. 2016;17:514–8.
17. Lavan AH, O’Mahony D, O’Mahony D, Gallagher P. Potentially inappropriate medication (PIM) use and severe drug interactions (SDIs) in older adults with cancer. J Geriatr Oncol. 2021;12:872–80.
18. Wenedy A, Lim YQ, Lin Ronggui CK, Koh GCH, Chong PH, Chew LS. A study of medication use of Cancer and non‑Cancer patients in home hospice Care in Singapore: a retrospective study from 2011 to 2015. J Palliat Med. 2019;22:1242–51.
19. McLean S, Seehey-Skeiffington B, O’Leary N, O’Gorman A. Pharmacological management of co‑morbid conditions at the end of life: is less more? Ir J Med Sci. 2013;182:107–12.
20. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American geriatrics society updated bevers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:16–31.
21. Ham L, Geijerstam ECT, Aarts MJ, Kuiper JG, Kunst PWA, Raimakers NJH, et al. Use of potentially inappropriate medication in older patients with lung cancer at the end of life. J Geriatr Oncol. 2022;13:53–9.
22. Arevalo JJ, Geijtenbeek ECT, Huisman BAA, Dees MK, Zuurmond WWA, van Zylen L, et al. Medication use in the last days of life in hospital, hospice, and home settings in the Netherlands. J Palliat Med. 2018;21:149–55.

23. Boddart MS, Stoppelenburg A, Hasselaar J, van der Linden YM, Vissers KCP, Rajmakers N.J.H, et al. Specialist palliative care teams and characteristics related to referral rate: a national cross-sectional survey among hospitals in the Netherlands. BMC Palliat Care. 2021;20:175.

24. Paque K, Vander Stichele R, Elseviers M, Pardon K, Dilles T, Deliens L, et al. Barriers and enablers to deprescribing in people with a life-limiting disease: a systematic review. Palliat Med. 2019;33:37–48.

25. Howland RH. Effects of aging on pharmacokinetic and pharmacodynamic drug processes. J Psychosoc Nurs Ment Health Serv. 2009;47:15–8.

26. Takahashi M, Matsui M, Inoue R, Uchino N. Potentially inappropriate medication discontinued or changed based on pharmacists’ recommendations in older end-stage cancer patients receiving palliative care: a cross-sectional study. Ann Palliat Med. 2021;10:11301–7.

27. Sera L, McPherson ML, Holmes HM. Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Med. 2014;31:126–31.

28. Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer. 2009;17:745–8.

29. Pruskowsk J. Fast facts and concepts #321. Deprescribing. Wisconsin: Palliative Care Network of Wisconsin, 2016.

30. Todd A, Holmes HM. Recommendations to support deprescribing medications late in life. Int J Clin Pharm. 2015;37:678–81.

31. Kunter JS, Blatchford PJ, Taylor DH, Ritchie CS, Bull JH, Fairclough DL, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175:691.

32. Oliveira L, Ferreira MO, Rola A, Magalhães M, Ferraz GJ. Deprescription in advanced cancer patients referred to palliative care. J Pain Palliat Care Pharmacother. 2016;30:201–5.

33. Narayan SW, Nishtala PS. Population-based study examining the utilization of preventive medicines by older people in the last year of life: preventive medicines at end-of-life. Geriatr Gerontol Int. 2018;18:892–8.

34. van Nordennen RTCM, Lavrijsen JCM, Vissers KCP, Koopmans RTCM. Decision making about change of medication for comorbid disease at the end of life: an integrative review. Drugs Aging. 2014;31:501–12.

35. Lindsay J, Dooley M, Martin J, Fay M, Khatun M, et al. The development and evaluation of an oncological palliative care deprescribing guideline: the ‘OncPal deprescribing guideline’. Support Care Cancer. 2015;23:71–8.

36. Noble S, Johnson M. Finding the evidence for thromboprophylaxis in palliative care: first let us agree on the question. Palliat Med. 2010;24:359–61.

37. King EJ, Haboubi H, Evans D, Baker I, Bain SC, Stephens JW. The management of diabetes in terminal illness related to cancer. QJM. 2012;105:3–9.

38. Jeffreys E, Rosielle D. Fast facts and concepts #258 diabetes Management at the end-of-Life. Wisconsin: Palliative Care Network of Wisconsin, 2015.

39. Ford-Dunn S, Smith A, Quin J. Management of diabetes during the last days of life: attitudes of consultant diabetologists and consultant palliative care physicians in the UK. Palliat Med. 2006;20:197–203.

40. World Health Organization. WHO essential medicines in Palliative Care. Geneva: WHO, 2013.

41. Lindqvist O, Lundquist G, Dickman A, Bukki J, Lunder U, Hagelin CL, et al. Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion. J Palliat Med. 2013;16:38–43.